Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/pathogens9050320 http://scihub22266oqcxt.onion/10.3390/pathogens9050320 32357471!7281371!32357471     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pathogens 2020 ; 9 (5): ä Nephropedia Template TP {{tp|p=32357471|t=2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs |pdf=|usr=}}{{32357471}} gab.com Text Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs JO: Pathogens http://www.kidney.de/pget.php?&tw=1&pmid=32357471 #FOAvip Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors. Twit Text FOAVip Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs ????Pathogens http://www.kidney.de/pget.php?&tw=1&pmid=32357471 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32357471 #FOAvip English Wikipedia <ref>{{Cite pmid|32357471}}</ref> Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs #MMPMID32357471 Neogi U; Hill KJ; Ambikan AT; Heng X; Quinn TP; Byrareddy SN; Sonnerborg A; Sarafianos SG; Singh K Pathogens 2020[Apr]; 9 (5): ä PMID32357471show ga Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors. äFeasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drug(epmc).pdf DeepDyve Pubget Overpricing